Abbvie

Natera is a leading molecular diagnostics company based in San Carlos, CA. They specialize in providing noninvasive cell-free DNA tests that help inform personalized healthcare decisions. Their tests measure fetal, tumor, or donor cfDNA at the molecular level, allowing for the identification of disease risk, detection of recurrence, and understanding of treatment responses. Natera is dedicated to advancing healthcare in the fields of oncology, women's health, and organ health, offering innovative solutions that enable more informed health decisions for individualized care. With a commitment to integrity and scientific rigor, Natera is at the forefront of molecular diagnostics innovation. Their oncology tests allow for the characterization of tumors, anticipation of risk, and evaluation of treatment response earlier than traditional tools. In the field of women's health, Natera's tests help identify the risk of severe genetic conditions, enabling families to prepare and inform early intervention for improved outcomes. Additionally, their organ health tests detect organ injury early and inform treatment strategies to enhance transplant health. Natera's dedication to innovation and integrity sets them apart as a trusted provider of molecular diagnostic solutions.Generated from the website

Rigel Pharmaceuticals is a biotechnology company based in South San Francisco, CA, dedicated to the discovery, development, and provision of innovative therapies that significantly enhance the lives of patients with hematologic disorders and cancer. The company's pipeline includes proprietary programs such as IRAK1 and RIPK1, as well as partnered programs with leading pharmaceutical companies like BerGenBio, Daiichi-Sankyo, Grifols, Kissei Knight, Lilly, Medison, and Novo Nordisk. Rigel Pharmaceuticals is committed to developing novel treatments, including TAVALISSE for thrombocytopenia in adult patients with chronic immune thrombocytopenia and REZLIDHIA for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.Generated from the website